Latest Interim analysis Stories
Enrollment in Worldwide Trial Continues as Planned REDMOND, Wash., Sept.
Interim results of the EFFORTLESS registry published in the European Heart Journal NATICK, Mass., April 1, 2014 /PRNewswire/ -- Real-world data on the Boston Scientific Corporation (NYSE:BSX)
Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial.
HUDDINGE, Sweden, February 22, 2011 /PRNewswire-FirstCall/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR (C205) study of TMC435 in treatment-naive patients with hepatitis C virus (HCV) genotype-1. - TMC435 was safe and well tolerated with no clinically relevant differences in adverse events between treatment groups and standard of care...
NATICK, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the current issue of Circulation.
SYDNEY, Australia and BEDMINSTER, N.J., Sept. 1 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.
- A political dynamiter.